Pediatric urologic oncology

Urol Clin North Am. 1985 Feb;12(1):31-42.

Abstract

Effective chemotherapy combined with surgery has produced excellent disease-free survival rates in most children with genitourinary malignancy. For patients with Wilms' tumor, the overall 2-year survival rate with no evidence of disease is greater than 90 per cent, and the interval of chemotherapy continues to be reduced for those children with low-stage lesions and favorable histologic patterns. In children with pelvic rhabdomyosarcoma, primary cytoreductive chemotherapy has proved to be an effective alternative to exenterative surgery. Patients with yolk-sac tumor who have localized disease need not be subjected to the potential morbidity of retroperitoneal lymph-adenectomy or the toxicity of adjuvant chemotherapy. Conversely, patients with advanced disease can be salvaged with recently developed combination chemotherapeutic regimens.

Publication types

  • Review

MeSH terms

  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Kidney Neoplasms / diagnosis
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / radiotherapy
  • Kidney Neoplasms / surgery
  • Male
  • Mesonephroma / pathology
  • Mesonephroma / therapy
  • Neoplasm Staging
  • Neuroblastoma / analysis
  • Neuroblastoma / diagnosis
  • Neuroblastoma / pathology
  • Neuroblastoma / therapy
  • Prognosis
  • Prostatic Neoplasms / pathology
  • Rhabdomyosarcoma* / pathology
  • Rhabdomyosarcoma* / therapy
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / therapy
  • Urinary Bladder Neoplasms / pathology
  • Urologic Neoplasms* / diagnosis
  • Urologic Neoplasms* / pathology
  • Urologic Neoplasms* / therapy
  • Uterine Neoplasms / pathology
  • Vaginal Neoplasms / pathology
  • Wilms Tumor* / diagnosis
  • Wilms Tumor* / drug therapy
  • Wilms Tumor* / pathology
  • Wilms Tumor* / radiotherapy
  • Wilms Tumor* / surgery